The global neoantigen oncology immunotherapy market is currently experiencing a dynamic period of expansion, fueled by substantial progress in immunogenomics and a growing understanding of the immune system's capability in combating tumors. Predictions indicate a continued expansion in the next years, driven by experimental assessments demonstratin